Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorYongtao Sun
About this trial
This study aims to investigate the ED50 and ED95 of nalbuphine combined with dexmedetomidine in patient-controlled intravenous analgesia (PCIA) for elderly patients with different degrees of frailty, as well as their analgesic effects and complications. The results of this study can provide safe and effective dosage guidance for postoperative analgesia in frail patients, help optimize analgesic regimens, reduce the risk of complications, and improve the quality of postoperative recovery.
Eligibility criteria
Qualifiers
Patients who plan to undergo elective gastrointestinal surgery and are expected to stay in hospital for ≥3 days after surgery [except abdominal perineal combined with radical resection of rectal cancer (MILES)];
ASA grade I-Ⅳ;
Age ≥65 years (2);
18.5 kg/m²≤BMI<30 kg/m²;
Disqualifiers
Severe cardiopulmonary, liver, kidney and coagulation dysfunction
Chemotherapy and radiotherapy were administered 1 month before surgery, and sedatives, antiemetic or antipruritic drugs were administered 24 hours before surgery
History of drug abuse, chronic pain, mental illness, or allergy to the drugs used in this study
Plan postoperative intubation or transfer to ICU;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
120 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Yongtao Sun
Lead sponsor
Qianfoshan Hospital
Sponsor institution
Source ClinicalTrials.gov